Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9925280 | 0.93 | PLA2G10 (0.34) | ALDH1A1 | |
| SCHEMBL3700587 | 0.85 | PLA2G10 (0.38) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20750016 | 0.83 | KMT2A (0.41) | ALDH1A1 | |
| SCHEMBL10475746 | 0.83 | ALOX15 (0.37) | ALDH1A1TSHRCYP2C19SMN1; SMN2 | |
| SCHEMBL12906770 | 0.83 | ALOX15 (0.37) | ALDH1A1TSHRCYP2C19SMN1; SMN2 | |
| SCHEMBL18118469 | 0.83 | ALOX15 (0.37) | ALDH1A1TSHRCYP2C19SMN1; SMN2 | |
| SCHEMBL12092238 | 0.82 | TACR1 (0.36) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL15518427 | 0.81 | HSD17B10 (0.39) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL560792 | 0.81 | HSD17B10 (0.39) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL30069168 | 0.80 | PLA2G10 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | ALDH1A1 1912/4885CYP1A2 1440/4885CYP3A4 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.